Mesoblast (MESO) Retained Earnings (2015 - 2025)
Mesoblast (MESO) posted quarterly Retained Earnings of $106.3 million for Q4 2025, up 8.74% year-on-year from $97.8 million in Q4 2024, and up 6.83% on a QoQ basis from $99.5 million in Q2 2025.
Mesoblast (MESO) Retained Earnings (2015 - 2025) Analysis & Trends
Mesoblast (MESO) has reported Retained Earnings for 11 consecutive years, with $106.3 million the latest figure, recorded in Q4 2025.
- Quarterly Retained Earnings rose 8.74% year-over-year to $106.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $106.3 million (up 8.74% YoY) and the FY2025 annual result came in at $99.5 million, up 110.95% from the prior year.
- Retained Earnings climbed to $106.3 million in Q4 2025 per MESO's latest filing, from $99.5 million in the prior quarter.
- Over the last five years, Retained Earnings for MESO reached as high as $106.3 million in Q4 2025 and fell as low as -$908.8 million in Q2 2024.
- A 5-year average of $16.5 million and a median of $73.6 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings tumbled 996.51% — and 2025, when it soared 110.95%.
- Year by year, Retained Earnings stood at $68.1 million in 2021, then grew by 6.6% to $72.6 million in 2022, then rose by 4.51% to $75.8 million in 2023, then rose by 28.88% to $97.8 million in 2024, then grew by 8.74% to $106.3 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered $106.3 million, $99.5 million, and $97.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | 106.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 106.29 Mn |
| Jun 30, 2025 | 99.50 Mn |
| Dec 31, 2024 | 97.75 Mn |
| Jun 30, 2024 | -908.76 Mn |
| Dec 31, 2023 | 75.85 Mn |
| Jun 30, 2023 | 101.37 Mn |
| Mar 31, 2023 | 73.55 Mn |
| Dec 31, 2022 | 72.57 Mn |
| Sep 30, 2022 | 70.87 Mn |
| Jun 30, 2022 | 97.92 Mn |
| Mar 31, 2022 | 69.28 Mn |
| Dec 31, 2021 | 68.08 Mn |
| Sep 30, 2021 | 66.47 Mn |
| Jun 30, 2021 | 92.86 Mn |
| Mar 31, 2021 | 64.25 Mn |
| Dec 31, 2020 | 52.19 Mn |
| Sep 30, 2020 | 48.80 Mn |
| Jun 30, 2020 | 85.33 Mn |
| Mar 31, 2020 | 43.51 Mn |
| Dec 31, 2019 | 42.05 Mn |